| Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. | |
| | |
MedLine Citation:
|
PMID: 17893375 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Exposure to excess aldosterone results in cardiac damage in hypertensive states. We evaluated the long-term cardiac structural and functional evolution in patients with primary aldosteronism after surgical or medical treatment. Fifty-four patients with primary aldosteronism were enrolled in a prospective study and were followed for a mean of 6.4 years after treatment with adrenalectomy (n=24) or spironolactone (n=30). At baseline, echocardiographic measurements of patients with primary aldosteronism were compared with those of 274 patients with essential hypertension. Patients with primary aldosteronism had greater left ventricular mass, more prevalent left ventricular hypertrophy, lower early:late-wave diastolic filling velocities ratio, and longer deceleration time than patients with essential hypertension but no differences in relative wall thickness and systolic function. During follow-up, average blood pressure was 135/82 and 137/82 mm Hg in patients treated with adrenalectomy and spironolactone, respectively. In the initial 1-year period, left ventricular mass decreased significantly only in adrenalectomized patients. Subsequent changes in left ventricular mass were greater in patients treated with spironolactone, with an overall change from baseline to the end of follow-up that was comparable in the 2 groups. Prevalence of hypertrophy decreased in both treatment groups, whereas diastolic parameters had only mild and nonsignificant improvement. Changes in blood pressure and pretreatment plasma aldosterone were independent predictors of left ventricular mass decrease in both treatment groups. Thus, in the long-term, both adrenalectomy and spironolactone are effective in reducing left ventricular mass in patients with primary aldosteronism, with effects that are partially independent of blood pressure changes. |
| | |
Authors:
|
Cristiana Catena; GianLuca Colussi; Roberta Lapenna; Elisa Nadalini; Alessandra Chiuch; Pasquale Gianfagna; Leonardo A Sechi |
Related Documents
:
|
15901525 - Hypertension in a patient with aldosterone deficiency. 16522995 - Resistant or difficult-to-treat hypertension. 20102385 - Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in... 17884095 - A combined dexamethasone/corticotropin-releasing hormone test in patients with chronic ... 21133825 - The prevalence of adolescent hypertension in hungary - the debrecen hypertension study. 9783485 - The epidemiology of the association between hypertension and menopause. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2007-09-24 |
Journal Detail:
|
Title: Hypertension Volume: 50 ISSN: 1524-4563 ISO Abbreviation: Hypertension Publication Date: 2007 Nov |
Date Detail:
|
Created Date: 2007-10-18 Completed Date: 2007-11-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7906255 Medline TA: Hypertension Country: United States |
Other Details:
|
Languages: eng Pagination: 911-8 Citation Subset: IM |
Affiliation:
|
Division of Internal Medicine, Hypertension and Cardiovascular Unit, Department of Experimental and Clinical Pathology and Medicine, University of Udine, Udine, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenoma
/
surgery* Adrenal Gland Neoplasms / surgery* Adrenalectomy* Aldosterone / blood Antihypertensive Agents / therapeutic use Female Follow-Up Studies Humans Hyperaldosteronism / complications, physiopathology*, therapy Hypertension / complications, drug therapy, physiopathology* Hypertrophy, Left Ventricular / etiology, physiopathology, therapy* Male Middle Aged Potassium / blood Prospective Studies Receptors, Mineralocorticoid / antagonists & inhibitors* Renin / blood Spironolactone / therapeutic use Time |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Receptors, Mineralocorticoid; 52-01-7/Spironolactone; 52-39-1/Aldosterone; 7440-09-7/Potassium; EC 3.4.23.15/Renin |
| Comments/Corrections | |
Comment In:
|
Hypertension. 2007 Nov;50(5):837-9
[PMID:
17909118
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Fourier analysis of the envelope of the ophthalmic artery blood flow velocity: age- and blood pressu...
Next Document: Antecedent blood pressure, body mass index, and the risk of incident heart failure in later life.